In addition to the Hang Seng Hong Kong Stock Connect Innovative Medicine Index and the SZSE Hong Kong Stock Connect Innovative Medicine Index, other mainstream indices focusing on the Hong Kong Stock Connect pharmaceutical sector include the CSI Hong Kong Stock Connect Innovative Medicine Index, the Hang Seng Hong Kong Stock Connect Healthcare Index, and the CSI Hong Kong Stock Connect Pharmaceutical Index.

The CSI Hong Kong Stock Connect Innovative Medicine Index is similar to the SZSE Hong Kong Stock Connect Innovative Medicine Index, covering 50 companies in the Hong Kong Stock Connect that are engaged in innovative drug R&D and contract research services (CXO), with a focus on the entire innovative drug industry chain. There are 2 ETFs tracking this index, with an average comprehensive fee rate of 0.60% per year.

The Hang Seng Hong Kong Stock Connect Healthcare Index selects 40 large healthcare companies tradable through the Hong Kong Stock Connect, with a weighting concentrated in leading biotechnology and pharmaceutical companies. There is 1 ETF tracking this index, with a comprehensive fee rate of 0.60% per year.

The CSI Hong Kong Stock Connect Pharmaceutical Index selects 50 companies in the Hong Kong Stock Connect with good liquidity and large market capitalization in the pharmaceutical and healthcare industry, covering the entire field including pharmaceuticals, distribution, and services, with a more dispersed industry distribution. There are 4 ETFs tracking this index, among which the Hong Kong Stock Connect Pharmaceutical ETF (513200, OTC Link A: 018557; C: 018558) has a comprehensive fee rate of only 0.20% per year, the lowest among similar products, while the other 3 products all have a comprehensive fee rate of 0.60% per year. In the first half of 2025, this fund achieved a return rate of 46.20%, ranking first among its peers.